Cell Biochemistry and Biophysics

, Volume 73, Issue 2, pp 519–525 | Cite as

RETRACTED ARTICLE: VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway

  • Jian Zhao
  • Zi-Ru Zhang
  • Na Zhao
  • Bao-An Ma
  • Qing-Yu Fan
Original Paper


Vascular endothelial growth factor (VEGF) is one of the most effective angiogenic factors that promote generation of tumor vasculature. VEGF is usually up-regulated in multiple cancers including osteosarcoma and glioma. To further explore the potential molecular mechanism that inhibits tumor growth induced by interference of VEGF expression, we constructed a Lv-shVEGF vector and assessed the efficiency of VEGF silencing and its influence in U2OS cells. The data demonstrate that Lv-shVEGF has high inhibition efficiency on VEGF expression, which inhibits proliferation and promotes apoptosis of U2OS cells in vitro. Our results also indicate that inhibition of VEGF expression suppresses osteosarcoma tumor growth in vivo and reduces osteosarcoma angiogenesis. We also found that the activations of phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) were considerably reduced after osteosarcoma cells were treated with Lv-shVEGF. Taken together, our data demonstrate that VEGF silencing suppresses cell proliferation, promotes cell apoptosis, and reduces osteosarcoma angiogenesis through inactivation of PI3K/AKT signaling pathway.


Cell apoptosis Angiogenesis Lentivirus-mediated short hairpin RNA (Lv-shRNA) U2OS cells Vascular endothelial growth factor (VEGF) 


  1. 1.
    Wang, S. W., et al. (2014). CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis, 35(12), 2633–2642.CrossRefGoogle Scholar
  2. 2.
    Xu, M., et al. (2014). Adenovirus-mediated ING4 gene transfer in osteosarcoma suppresses tumor growth via induction of apoptosis and inhibition of tumor angiogenesis. Technology Cancer Research and Treatment. doi: 10.7785/tcrt.2012.500424.Google Scholar
  3. 3.
    DuBois, S., & Demetri, G. (2007). Markers of angiogenesis and clinical features in patients with sarcoma. Cancer, 109(5), 813–819.CrossRefPubMedGoogle Scholar
  4. 4.
    Mikulic, D., et al. (2004). Tumor angiogenesis and outcome in osteosarcoma. Journal of Pediatric Hematology Oncology, 21(7), 611–619.CrossRefPubMedGoogle Scholar
  5. 5.
    Jendreyko, N., et al. (2005). Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102(23), 8293–8298.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mosch, B., et al. (2010). Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. Jounal of Oncology, 2010, 135285.Google Scholar
  7. 7.
    Jin, X., et al. (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Research, 71(22), 7125–7134.CrossRefPubMedGoogle Scholar
  8. 8.
    Weiss, K. R., et al. (2006). VEGF and BMP expression in mouse osteosarcoma cells. Clinical Orthopaedics and Related Research, 450, 111–117.CrossRefPubMedGoogle Scholar
  9. 9.
    Won, Y. W., et al. (2012). Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion. Journal of Controlled Release, 160(3), 525–531.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wei, M. H., et al. (1996). Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Human Genetics, 97(6), 794–797.CrossRefPubMedGoogle Scholar
  11. 11.
    Leidi, M., Mariotti, M., & Maier, J. A. (2010). EDF-1 contributes to the regulation of nitric oxide release in VEGF-treated human endothelial cells. European Journal of Cell Biology, 89(9), 654–660.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhu, K. Q., et al. (2005). Changes in VEGF and nitric oxide after deep dermal injury in the female, red Duroc pig-further similarities between female, Duroc scar and human hypertrophic scar. Burns, 31(1), 5–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Baker, G. J., et al. (2014). Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia, 16(7), 543–561.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lee, L., et al. (2006). Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemotherapy and Pharmacology, 57(6), 761–771.CrossRefPubMedGoogle Scholar
  15. 15.
    Fukuhara, M., et al. (2005). Re-expression of reduced VEGF activity in liver metastases of experimental pancreatic cancer. Journal of Nippon Medical School, 72(3), 155–164.CrossRefPubMedGoogle Scholar
  16. 16.
    Ohba, T., et al. (2014). Autocrine VEGF/VEGFR1 signaling in a subpopulation of cells associates with aggressive osteosarcoma. Molecular Cancer Research, 12(8), 1100–1111.CrossRefPubMedGoogle Scholar
  17. 17.
    Roorda, B. D., et al. (2010). VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. European Journal of Cancer, 46(5), 974–982.CrossRefPubMedGoogle Scholar
  18. 18.
    Kawashima, H., et al. (2003). Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma. Cancer Science, 94(1), 70–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamaguchi, H., et al. (1988). The alteration in the pattern of pulmonary metastasis with adjuvant chemotherapy in osteosarcoma. International Orthopaedics, 12(4), 305–308.CrossRefPubMedGoogle Scholar
  20. 20.
    Bielack, S., Carrle, D., & Jost, L. (2008). Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. The Annals of Oncology, 19(Suppl 2), ii94–ii96.PubMedGoogle Scholar
  21. 21.
    Courties, G., et al. (2009). RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 9(5), 535–538.CrossRefPubMedGoogle Scholar
  22. 22.
    Valdehita, A., et al. (2012). RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Molecular and Cellular Endocrinology, 348(1), 241–246.CrossRefPubMedGoogle Scholar
  23. 23.
    Qi, L., et al. (2014). Effects of VEGF suppression by small hairpin RNA interference combined with radiotherapy on the growth of cervical cancer. Genetics and Molecular Research, 13(3), 5094–5106.CrossRefPubMedGoogle Scholar
  24. 24.
    Majeti, B. K., et al. (2013). VEGF is an important mediator of tumor angiogenesis in malignant lesions in a genetically engineered mouse model of lung adenocarcinoma. BMC Cancer, 13, 213.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wu, J., et al. (2012). Short Hairpin RNA (shRNA) Ether a go–go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3 K/AKT signaling. International Journal of Molecular Sciences, 13(10), 12573–12583.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kitamura, T., et al. (2008). Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nature Cell Biology, 10(3), 329–337.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jian Zhao
    • 1
  • Zi-Ru Zhang
    • 1
  • Na Zhao
    • 2
  • Bao-An Ma
    • 1
  • Qing-Yu Fan
    • 1
  1. 1.Department of Orthopedic Surgery, Tangdu Hospital, Orthopedics Oncology Institute of Chinese PLAFourth Military Medical UniversityXi’anChina
  2. 2.Outpatient Department, Tangdu HospitalFourth Military Medical UniversityXi’anChina

Personalised recommendations